Thursday, August 18, 2016 3:50:33 PM
The biomarker assay was not used with patients in the study/data that was presented at the Annual AACR Meeting in April. These patients were enrolled in our Phase II melanoma monotherapy study. After completion of our study, some patients went on to receive anti-PD-1 therapy. Researchers documented and analyzed long-term follow-up data after they received anti-PD-1 treatment.
The biomarker assay is currently being used to select patients for the ongoing Phase II clinical trial evaluating the combination of OncoSec's ImmunoPulse IL-12 and pembrolizumab in melanoma patients. We're using the assay's ability to select patients, who are unlikely to respond to anti-PD-1, and enroll these patients in our Phase II combination trial. Data from this trial is expected to be presented in 2016.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM